A61K 47/6857
The tumour determinant being from lung cancer cell
Official title: {the tumour determinant being from lung cancer cell}
A61K47/6857 (The tumour determinant being from lung cancer cell) appears on 229 US grants and 412 published applications in this corpus.
Search patents in A61K- Granted patents
- 229
- Published applications
- 412
- Assignees
- 134
- Inventors
- 728
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 5 |
| 2007 | 2 | 5 |
| 2008 | 3 | 4 |
| 2009 | 5 | 7 |
| 2010 | 1 | 4 |
| 2011 | 6 | 6 |
| 2012 | 2 | 6 |
| 2013 | 7 | 8 |
| 2014 | 6 | 27 |
| 2015 | 22 | 19 |
| 2016 | 23 | 35 |
| 2017 | 18 | 34 |
| 2018 | 25 | 37 |
| 2019 | 15 | 30 |
| 2020 | 14 | 26 |
| 2021 | 23 | 30 |
| 2022 | 12 | 25 |
| 2023 | 15 | 23 |
| 2024 | 10 | 24 |
| 2025 | 9 | 32 |
| 2026 | 6 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibodies binding AXL31 Mar 2026US 12,589,150 B2Genmab A/S
- Compositions and methods for the diagnosis and treatment of tumor24 Mar 2026US 12,583,937 B2Genentech, Inc.
- CEACAM5 antibody-drug conjugate formulation3 Mar 2026US 12,564,642 B2Sanofi
- Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof10 Feb 2026US 12,545,735 B2Regeneron Pharmaceuticals, Inc.
- Splicing modulator antibody-drug conjugates and methods of use6 Jan 2026US 12,514,926 B2Eisai R&D Management Co., Ltd.
- Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof20 Aug 2026US 2026/0242515 A1Duality Biologics (Shanghai) Co., Ltd.
- Herboxidiene antibody-drug conjugates and methods of use6 Aug 2026US 2026/0224730 A1Eisai R&D Management Co., Ltd.
- Compositions and methods for targeting and treating tumor30 Jul 2026US 2026/0216335 A1Jiangsu Code Biomedical Technology Co., Ltd.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof30 Jul 2026US 2026/0216354 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Antibody-drug conjugates against the receptor tyrosine kinase epha530 Jul 2026US 2026/0216365 A1MBrace Therapeutics, Inc.
Most cited
By later US patents
- Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents147US 7,303,749 B1ImmunoGen, Inc. · 2007
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates76US 8,268,317 B2Immunomedics, Inc. · 2012